Form 4 for ONC BeOne Medicines Ltd.
Accepted 2024-06-07 00:00:00 ET · period of report 2024-06-05 · accession 0001651308-24-000068 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-06-07 | 2024-06-05 | ONC | Wu Xiaobin | Pres, COO, GM China | A - Grant | $0.00 | +253.4K | 1.27M | +25% | $0 |
| D | 2024-06-07 | 2024-06-05 | ONC | Wu Xiaobin | Pres, COO, GM China | A - Grant | $0.00 | +477.4K | 477.4K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2024-06-05 | A | A | 253,409 | $0.00 | 1,268,849 | D | — | — | (F1) Represents securities underlying restricted share units. 1/4th of the securities will vest on each anniversary of June 5, 2024, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events. (F2) Includes 1,443 ordinary shares acquired pursuant to the Company's Third Amended and Restated 2018 Employee Share Purchase Plan. |
| 2 | Derivative | Share Option (Right to Buy) | 2024-06-05 | A | A | 477,386 | $0.00 | 477,386 | D | $12.23 · — to 2034-06-04 | 477,386 Ordinary Shares | (F7) The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. (F8) These securities vest over a four-year period as follows: 25% on the first anniversary of June 5, 2024, and the remaining in 36 successive equal monthly installments, subject to continued service. Unvested shares are subject to accelerated vesting upon certain termination events. |